A coloring composition containing one or more species of compounds represented by Formula (I) or Formula (II) below, wherein each of R.sub.1 and R.sub.2 represents a hydrogen atom or substituent, each of Ar.sub.1 to Ar.sub.8 independently represents an optionally substituted aromatic hydrocarbon group or optionally substituted heterocyclic group, and each of L.sub.1 and L.sub.2 independently represents a divalent linking group which interrupts ? electron conjugated system: ##STR00001##

Problem to Be Solved: to provide a chromophore having a far superior nonlinear optical activity to conventional chromophores and to provide a nonlinear optical element comprising said chromophore.

Solution: a chromophore comprising a donor structure D, a -conjugated bridge structure B, and an acceptor structure A, the donor structure D comprising an aryl group substituted with a substituted oxy group; and a nonlinear optical element comprising said chromophore.

Problem to Be Solved: to provide a chromophore having a far superior nonlinear optical activity to conventional chromophores and to provide a nonlinear optical element comprising said chromophore. Solution: a chromophore comprising a donor structure D, a -conjugated bridge structure B, and an acceptor structure A, the donor structure D comprising an aryl group substituted with a substituted oxy group; and a nonlinear optical element comprising said chromophore.

The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.

A pigment composition including: a first cholesteric liquid crystal pigment; and a second cholesteric liquid crystal pigment, wherein: the first cholesteric liquid crystal pigment is a pigment having: a center wavelength of a selective reflection band within a wavelength range of 400 nm or more and 800 nm or less; and a selective reflection bandwidth of 150 nm or less; the second cholesteric liquid crystal pigment is a pigment having a selective reflection bandwidth of 200 nm or more within a wavelength range of 400 nm or more and 800 nm or less; the selective reflection band of the first cholesteric liquid crystal pigment and a selective reflection band of the second cholesteric liquid crystal pigment at least partially overlap with each other; and a containing amount of the first cholesteric liquid crystal pigment relative to a total amount of the first cholesteric liquid crystal pigment and the second cholesteric liquid crystal pigment is more than 0% by weight and 30% by weight or less.

A pigment composition includes first and second cholesteric liquid crystal pigments. The first cholesteric liquid crystal pigment has a center wavelength of a selective reflection band within a wavelength range of 400 nm or more and 800 nm or less and a selective reflection bandwidth of 150 nm or less. The second cholesteric liquid crystal pigment has a selective reflection bandwidth of 200 nm or more within a wavelength range of 400 nm or more and 800 nm or less. The selective reflection band of the first cholesteric liquid crystal pigment and a selective reflection band of the second cholesteric liquid crystal pigment at least partially overlap with each other. A containing amount of the first cholesteric liquid crystal pigment relative to a total amount of the first and second cholesteric liquid crystal pigments is more than 30% by weight and 80% by weight or less.

The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.